Author: admin

  • Jim Shannon – 2016 Parliamentary Question to the Department of Health

    Jim Shannon – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Shannon on 2016-05-23.

    To ask the Secretary of State for Health, what steps his Department is taking to reduce the use of antibiotics.

    Jane Ellison

    The UK Five Year Antimicrobial Resistance Strategy is an ambitious programme to slow the development and spread of antimicrobial resistance, which was published in 2013. The Strategy aims to prevent infection, protect the antibiotics that we have and promote the development of new drugs and alternative treatments. Each of these initiatives will contribute to reductions in the inappropriate use of antibiotics.

    Implementation of our Strategy has met with success in primary care. Between April and December 2015, two million fewer prescriptions were dispensed compared to the same period in 2014, a reduction of 7.9%.

    Globally, the United Kingdom has been at the forefront of successful negotiations of the antimicrobial resistance resolution at World Health Organization last year, with equivalent resolutions relating to food and agriculture and animal health. A key part of this work is aimed at reducing the risk of infections and improving antimicrobial stewardship.

    We are also aiming to raise the profile of antimicrobial resistance yet higher through a successful high level meeting on antimicrobial resistance at the UN General Assembly in September this year.

    Furthermore, we will use the recently published recommendations from Lord O’Neill’s Review on antimicrobial resistance to address the global challenge of unblocking the antibiotic pipeline and reducing unnecessary antibiotic usage in both the human and animal health sectors.

  • Jim Shannon – 2016 Parliamentary Question to the Department of Health

    Jim Shannon – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Shannon on 2016-05-23.

    To ask the Secretary of State for Health, what discussions his Department has had with medical organisations on using DNA tests to help in the diagnosis and treatment of breast cancer.

    Jane Ellison

    We are not aware of any discussions with medical organisations on using DNA tests to help in the diagnosis, and treatment, of breast cancer.

  • Jim Shannon – 2016 Parliamentary Question to the Department of Health

    Jim Shannon – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Shannon on 2016-05-23.

    To ask the Secretary of State for Health, what discussions his Department has had with medical organisations on treatment of chronic bronchitis through the freezing of lungs.

    Jane Ellison

    There have been no such discussions.

  • Jim Shannon – 2016 Parliamentary Question to the Department of Health

    Jim Shannon – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Shannon on 2016-05-23.

    To ask the Secretary of State for Health, what discussions his Department has had with medical organisations on the use of aspirin to prevent strokes.

    George Freeman

    The National Institute for Health and Care Excellence’s (NICE) clinical guideline on stroke and transient ischaemic attack in over 16s: diagnosis and initial management (CG68), published in July 2008, recommends that all people presenting with acute stroke who have had a diagnosis of primary intracerebral haemorrhage excluded by brain imaging should be given aspirin 300 mg as soon as possible but certainly within 24 hours.

    Thereafter, aspirin 300 mg should be continued until two weeks after the onset of stroke symptoms, at which time definitive long-term antithrombotic treatment should be initiated.

    This guidance is due to be reviewed by NICE in July 2016 to see whether it needs to be updated.

  • Jim Shannon – 2016 Parliamentary Question to the Department of Health

    Jim Shannon – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Shannon on 2016-05-23.

    To ask the Secretary of State for Health, what discussions his Department has had with medical organisations on the potential link between high blood pressure in people of 30 to 40 years of age and the development of Alzheimer’s disease.

    Jane Ellison

    The Department has had no such discussions.

    Dementia is a key priority for this Government. That is why on 6 March 2016, we published the Implementation Plan to support the Prime Minister’s Challenge on Dementia 2020. As part of the Plan, we will transform our approach to risk reduction, using the NHS Health Check programme to educate more people earlier about the risks of developing dementia – and the steps they could take to reduce those risks.

    In March 2016, we announced that Public Health England, in collaboration with Alzheimer’s Society and Alzheimer’s Research UK, will pilot approaches to the dementia awareness and risk reduction component of the NHS Health Check, specifically with the younger age group, aged 40-64.

    The Government has also signed up to the Blackfriars’ Consensus, which, made clear that individuals can reduce their risk of dementia by living healthier lives by not smoking, drinking less, keeping physically active and better managing diabetes.

  • Fiona Bruce – 2016 Parliamentary Question to the Department of Health

    Fiona Bruce – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Fiona Bruce on 2016-05-23.

    To ask the Secretary of State for Health, with reference to the Answer of 11 March 2016 to Question 29747, whether any of the correspondence cited in the oral contribution of the Lord Patel on 24 February 2015 had been given unredacted to concurrently serving members of the Human Fertilisation and Embryology Authority executive.

    Jane Ellison

    The Human Fertilisation and Embryology Authority (HFEA) has advised that wider disclosure of the content of the personal email exchange between Professor Grifo and a member of the expert panel convened by the Authority would not breach patient confidentiality. The HFEA has previously advised that the relevant expert panel member contacted Professor Grifo in a personal capacity following the third Scientific Review of the safety and efficacy of methods to avoid mitochondrial disease in 2014.

    The HFEA has also advised that the information in question was provided in confidence to the expert panel convened by the Authority. Members of the HFEA Executive who provided administrative support to the work of the panel have seen this information.

  • Daniel Zeichner – 2016 Parliamentary Question to the Department of Health

    Daniel Zeichner – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Daniel Zeichner on 2016-05-23.

    To ask the Secretary of State for Health, what recent progress has been made on Public Health England’s study into the health impact of incinerators.

    Jane Ellison

    The Public Health England funded study by the Small Area Health Statistics Unit (SAHSU) at Imperial College and the Environmental Research Group at King’s College, London, investigating the potential link between emissions from municipal waste incinerators and health outcomes is ongoing. It is expected that papers from the project will be submitted by SAHSU to peer reviewed journals later in 2016.

  • Fiona Bruce – 2016 Parliamentary Question to the Department of Health

    Fiona Bruce – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Fiona Bruce on 2016-05-23.

    To ask the Secretary of State for Health, what assessment he has made of the effectiveness of the use of embryonic stem cell research for the development of treatments for patients.

    George Freeman

    Treatments based on the use of stem cells including those obtained by embryos must be demonstrated to be both safe and effective before they can receive authorisation.

  • Fiona Bruce – 2016 Parliamentary Question to the Department of Health

    Fiona Bruce – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Fiona Bruce on 2016-05-23.

    To ask the Secretary of State for Health, how many people have been treated with adult stem cells in the UK in each of the last 10 years.

    George Freeman

    The Department does not hold data on the number of patients receiving stem cell treatments.

  • Joan Ryan – 2016 Parliamentary Question to the Department of Health

    Joan Ryan – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Joan Ryan on 2016-05-23.

    To ask the Secretary of State for Health, what assessment he has made of the effect on patient confidentiality of the decision by NHS Royal Free Foundation Trust to grant DeepMind access to NHS patient records; and if he will make a statement.

    George Freeman

    Individual organisations providing National Health Service care are the data controllers for the information that they hold, and are responsible for ensuring that there is a legal basis for sharing confidential patient information with a third party.

    Individual organisations must ensure that where patient consent is the basis for information sharing that patients are fully informed about the purposes for which personal information might be processed and with whom they might share information. Where a NHS organisation has contracted a third party to process personal information on its behalf to support the provision of direct care to patients the individual organisation must ensure that it has contractual safeguards in place to prevent the third party from using the data for purposes other than those determined by the NHS organisation.

    NHS organisations should not share confidential patient information where the patient has objected – except in cases where there is a legal requirement to share data or an overriding public interest.